Summary Efficacy of cancer immunotherapy with cultured tumour-infiltrating lymphocytes (TlLs) depends upon infused TILs migrating into tumour-bearing tissue, in which they mediate an anti-tumour response. For TILs to enter a tumour, they must first bind to tumour endothelium, and this process depends on TILs expressing and regulating the function of relevant cell-surface receptors. We analysed the cell-surface phenotype and endothelial binding of TILs cultured from human melanoma and compared them with peripheral blood T cells and with allostimulated T cells cultured under similar conditions. Compared with peripheral blood T cells, TILs expressed high levels of five integrins, two other adhesion molecules, including the skin homing molecule CLA, and several activation markers and showed markedly enhanced integrin-mediated adhesion to a dermal microvascular endothelial cell line in vitro. Compared with the allostimulated T cells, TILs expressed higher levels of the cutaneous lymphocyte antigen (CLA), the adhesion molecule CD31 and the activation markers CD30 and CD69, but lower levels of several other adhesion and activation molecules. These phenotypic and functional properties of TILs should have complex effects on their migration in vivo. Expression of CLA, the skin homing receptor, may increase migration to melanoma (a skin cancer), whereas integrin activation may cause non-specific binding of TILs to other endothelium. Manipulation of the culture conditions in which TILs are expanded might result in a phenotype that is more conducive to selective tumour homing in vivo.
T lymphocyte-mediated mechanisms are believed to be an important part of the immune defence against certain human tumours, including the skin cancer malignant melanoma. Evidence for this comes from several sources: firstly, melanomas that regress 'spontaneously' are usually heavily infiltrated with T cells; secondly, T cells in melanomas are clonally expanded and show cytotoxicity against tumour cells bearing tumour-associated antigens (van der Bruggen et al, 1991) ; thirdly, adoptive immunotherapy with in vitro expanded tumour-infiltrating T lymphocytes (TILs) has proved successful in preliminary trials in patients with metastatic melanoma (Rosenberg et al, 1986 (Rosenberg et al, , 1988 , although some recent studies have been disappointing (Ravaud et al, 1995) .
Adoptive immunotherapy involves isolation of TILs from resected tumour, expansion in vitro by culturing in the presence of interleukin 2 (IL-2) and then reinfusion into the patient. In one study, radiolabelled TILs were detected in melanoma tumour deposits in 68% of cases (Pockaj et al, 1993) . However, only a small proportion of infused TILs migrate to tumour, and the majority are trapped in the liver, lungs and spleen (Grifflth et al, 1989 ; Whiteside and Herberman, 1992) . This means that large numbers of TILs need to be infused to ensure that at least some reach the tumour. Little is known about the mechanisms that determine the migration of infused TILs in vivo, and a better understanding of this process might suggest strategies to increase the efficiency with which infused TILs reach tumour deposits.
Adhesion to endothelium is the first, crucial step in the migration of T cells from the circulation into tissue, and this process is carefully regulated by sequential molecular steps (Adams and Shaw, 1994; Springer, 1994; Butcher and Picker, 1996) . Initially, selectin-mediated interactions cause circulating cells to slow their flow and roll along the vessel wall. Here, the T cell encounters 'triggering' factors (principally cytokines) present on the vessel wall that activate T-cell integrins (Springer, 1994; Tanaka et al, 1993 ). This step is crucial as integrins on circulating T cells do not bind well until activated (Shimizu et al, 1991a; Hynes, 1992) . Once activated, the integrins bind to endothelial adhesion molecules and bring the cell to a halt, allowing it to flatten and then migrate into tissue in response to local chemotactic factors.
The tethering step of T-cell adhesion is mediated by selectins in some circumstances and by integrins in others (Butcher and Picker, 1996) . Strong adhesion is mediated predominantly by two T-cell integrins; the ,2 integrin LFA-1, which binds to endothelial counter-receptors ICAM-1 and ICAM-2, and the PI integrin VLA-4, which binds to VCAM-1 (Shimizu et al, 1991a) . Selectivity is introduced by the existence of tissue-specific adhesion molecules on T cells that direct migration to particular organs (Butcher and Picker, 1996) . This is particularly relevant for the skin, in which T cells activated in peripheral lymph nodes express the cutaneous lymphocyte antigen (CLA), which allows them to bind to E-selectin expressed on dermal endothelium, thereby promoting skin tropism (Picker et al, 1990a (Picker et al, , 1993a Berg et al, 1991) . There is recent evidence that tumour-/tissue-specific 1422 OH Adams et al adhesion pathways can regulate the adhesion of TILs to tumour endothelium, suggesting that tissue-specific factors may regulate TIL recruitment to tumour in a manner analogous to that seen with normal T-cell recirculation (Salmi et al, 1992; Salmi et al, 1995; .
Thus, whether transfused TILs migrate back to sites of tumour or are 'lost' elsewhere will be determined by (1) the adhesion molecules expressed by the TILs and their state of activation; (2) the adhesion counter-receptors expressed by tumour endothelium; and (3) the adhesion counter-receptors on other host endothelium which would trap or recruit them elsewhere. We have undertaken an extensive phenotypic and functional analysis of TILs cultured from human melanoma to determine which adhesion molecules they express and use to bind endothelium in vitro. We have demonstrated that, compared with peripheral blood T cells, cultured TIL are highly activated with increased expression of several adhesion molecules and activation-dependent antigens.
Furthermore, they bind avidly in vitro to both resting and cytokine-activated endothelial monolayers. These characteristics of cultured TILs are likely to have a profound influence on their ability to migrate to tumours in vivo.
MATERIALS AND METHODS TIL preparations TIL preparations from seven patients with malignant melanoma were studied. TILs were prepared as described previously (Yannelli, 1991) . Briefly, tumour biopsies were removed from cancer patients in the Surgery Branch of the National Cancer Institute. Tumour tissue was cut into 1-to 3-mm3 chunks and digested overnight in collagenase type IV (1 jg ml-1), hyaluronidase (0.1 ,ug ml-') and DNAase (30 ,ug ml-'). After digestion, the single-cell suspensions were passed through a sterile wire screen grid, washed three times in calcium-and magnesium-free Hanks' balanced salt solution (HBSS) and passed over Ficoll-Hypaque gradients to remove dead cells and red blood cells. The TIL cell cultures were established with 5.0 x 105 total cells ml-1 in 24-well culture plates (Costar) in RPMI-1640 with 10% human AB serum (Bio-Whitaker, Walkersville, MD, USA) and antibiotics. This medium was mixed 1:1 (v/v) with AIM-V serum-free medium (Gibco, Grand Island, New York, NY, USA) and supplemented with 7200 IU ml-1 IL-2 (Cetus Emeryville, CA, USA) and 10% (v/v) lymphokine-activated killer cell-conditioned medium prepared as previously described (Yannelli, 1991) . TIL densities were maintained at 5.0 x 105 ml-1 by splitting every 3-5 days with fresh medium containing IL-2. TILs used in the study had been in culture for between 30 and 45 days.
Cells and culture reagents
Allostimulated T cells were used for comparison in the phenotypic studies. These cells were originally expanded for use in HLA typing by allostimulation with DP mismatched feeder cells. After 2 days, 15-20% T-cell growth factor (IL-2) was added to the cultures and the cells were then maintained in T-cell growth factor and restimulated with antigen every 7-10 days. Cells were cultured for a total of 24 days before being cryopreserved. The T-cell growth factor used was supernatant from 0.08% phytohaemagglutinin (PHA)-P activated peripheral blood lymphocytes that contained IL-2. These cells were chosen for comparison with TIL in the phenotypic studies because they had been stimulated with specific antigen and subsequently cultured in high doses of IL-2 and cryopreserved under similar conditions. However, there are obviously important differences between the two cell types, the allostimulated cells were CD4 T cells derived from peripheral blood, whereas TILs are usually CD8 and are derived from tissue.
Human peripheral blood T cells (PBTs) were isolated from normal donors by rigorous negative immunoselection with magnetic beads as previously described using a cocktail of monoclonal antibodies (MAbs) against HLA class II on B cells, activated T cells and monocytes (IVA12), CD20 on B cells (iF5), CD16 on NK cells (3G8), CD1ib on monocytes (NIH1lb-1), CD14 on monocytes (MMA) and glycophorin on erythrocytes (1OF7). Purity of the T cells was greater than 98%.
Human umbilical venous endothelial cells (HUVECs) were isolated and cultured as previously described (Shimizu et al, 1991a) in M199 media containing 20% fetal calf serum (FCS, Hyclone), 90 jg ml-1 preservative-free porcine heparin, 20 jg ml-1 endothelial cell growth supplement and antibiotics. All studies were done on confluent monolayers at passage 2 or less in 24-well plates (Costar).
The HMEC-1 dermal microvascular cell line was cultured as previously described (Ades et al, 1993) in EBM media (Clonetics) containing 10% FCS, 10 ng ml-1 epidermal growth factor (EGF) and 100 ng ml-' hydrocortisone plus antibiotics. All studies were done using confluent monolayers in 48-well plates (Costar).
Monoclonal antibodies
The antibodies used for the phenotypic studies are listed in Table 1 . Monoclonal antibodies were used as ascites fluid, culture supematant or purified antibody. All were used in saturating concentrations.
The following MAbs were used at 10 jg ml-1 purified antibody to block adhesion: NIHI lb-I (CDl lb/MAC-I a-chain) , MHM24 (CDIla/LFA-1 a-chain) (Hildreth et al, 1983) , MHM23 (CD18/12 integrin ,B-chain) (Hildreth et al, 1983) , 2G7 (VCAM-1) (Graber et al, 1990) , 7A9 (E-selectin) (Graber et al, 1990) , NIH45-2 (CD45) (Shimizu et al, 1991b) , MAb 84H10 (ICAM-1) (Makgoba et al, 1988) , L25 (VLA-4 a-chain) (Clayberger et al, 1987; Takada et al, 1989) , MAB-13 (Matsuyama et al, 1989) and 4B4 (Coulter Electronics, Hialeah, FL, USA) (CD29NLA 1-chain) (Matsuyama et al, 1989) , MAb-16 (VLA-5 a-chain) (Matsuyama et al, 1989) , Act-I (a417) (Lazarovits et al, 1984) , HML-1 (aIELP7) (Schieferdecker et al, 1990 ).
Flow cytometry
Cell surface phenotyping was done on TILs and PBTs as described previously (Schweighoffer et al, 1993) . Approximately 1-2 x 106 cells were washed twice with FACS medium (HBSS containing 0.2% human serum albumin and 0.2% sodium azide), incubated 
Cell adhesion assays
Binding to endothelium Binding of TILs and PBT to HUVECs was assessed as previously described (Shimizu et al, 1991a) . Briefly, HUVECs were plated onto gelatin-precoated 24-well plates (Costar) and cultured for 48 h until confluent, activated by exposure to 1 ng ml' IL-1p in medium (RPMI/10% FCS) for 4 h at 37°C and then washed twice with medium immediately before addition of T cells. TILs or PBTs were labelled with 51Cr, and 300 000 T cells were added to each well in a final volume of 300 gl. In order to assess adhesion of acutely activated T cells, cells were preactivated by incubation for 20 min with 10 ng ml' PMA (Sigma Chemical, St Louis, MO, USA) before washing and addition to the HUVEC monolayer. When blocking by MAbs was assessed, binding was carried out in the continuous presence of antibody; all MAbs were used at a saturating concentration of 10 gg ml-', which has been shown in previous studies to maximally inhibit the relevant adhesive interaction (Graber et al, 1990; Shimizu et al, 1990a, b, c; van Seventer et al, 1990) . Plates were incubated for 30 min at 37°C and then gently washed twice with RPMI/10% FCS media at room temperature to remove non-adherent T cells. Contents of each well containing adherent T cells were lysed with 300 gl of 1% Triton X-100 and y-emissions were counted. Data are expressed as mean per cent of cells binding [(counts from wells/counts from 300 000 lysed cells) x 1001. Because the differences observed between freshly isolated TIL and TIL that had been cryopreserved were small, cryopreserved TIL were used for most of the studies. Binding to HMEC-1 was assessed in a similar assay, except that cells were grown to confluence in EBM and then in RPMII10%
FCS for the final 18 h during which activation was done using 50 units ml-' TNF-a which has previously been shown to induce optimal activation of HMEC-1 (Swerlick et al, 1992) .
Actin polymerization
The morphology of TILs and PBTs and the distribution of polymerized filamentous actin (F-actin) were assessed by rhodamine phalloidin staining and laser scanning confocal microscopy. Cells were settled for at least 60 min at 37°C on plastic slides that had A been coated with 20 gg ml fibronectin. The cells were then fixed with 3.7% formaldehyde for at least 1 h at 4°C, permeabilized by incubating with 2 mg ml-' lysophosphatidyl choline (LPC) (Sigma) and total F-actin detected by staining with 300 units rhodamine-phalloidin for 30 min at 4°C. Cells that were fixed and stained with rhodamine-phalloidin were analysed with a Nikon Microphot-FX microscope (plan 40x objective lens) connected to a BioRad MRC 600 laser scanning confocal microscope (BioRad Life Sciences Group, Melville, NY, USA).
Statistics
Comparisons between groups were analysed using the Mann-Whitney U-test for non-parametric data. A level of 2P<0.05 was taken as significant. Trends were analysed using Kruskal-Wallis one-way ANOVA.
RESULTS
TIL have an abnormal highly activated morphology and cell surface phenotype All the TIL preparations studied were T cells (> 95% CD3 positive); six were predominantly CD8+ and one predominantly CD4+.
Although cultured TILs are T cells, they are markedly different from resting PBTs, with respect to both overall morphology and cell-surface phenotype. TILs are larger, more irregular and have increased foci of filamentous actin in the cytoskeleton, consistent with an activated state (Figure 1 ). TILs also have a markedly different phenotype from PBTs with respect to the levels of expression of cell-surface markers. We initially screened TIL preparations using 57 MAb reactive with 54 different T-cell surface molecules and compared them with activated cultured T cells (SB6) (using all MAbs) and with PBTs (using 29 of the MAbs). We have highlighted data obtained with 27 of these MAbs in Figure TILs have higher levels of many molecules than PBTs, consistent with their activated state. This scatterplot shows the median channel fluorescence of 27 antibodies to cell surface markers shown on TILs (median of the seven preparations) compared with the median channel fluorescence of each antibody on PBTs. The name of the molecule is positioned at the appropriate co-ordinates. A solid line marks the position for molecules expressed at equivalent levels on TILs and PBTs. The fine dotted lines represent the staining for each cell type with 1.9.9, an irrelevant mouse antibody. In all cases the background staining with 1.9.9 was higher on TILs than on PBTs (Table 1) TIL; or (3) probable relevance to migration. The excluded MAb were generally either negative on TIL or expressed at roughly equivalent levels on TIL and the other cell preps. approximately the same time and with similar IL-2 supplementation (Figure 3) . The allostimulated cells were predominantly CD4; however previous studies have shown that CD4 and CD8 T cells are similar in their surface phenotype with respect to many markers (Shaw et al, 1994 ). While we accept that these cells are not an ideal cell type for comparison with the TILs, we believe that they do provide useful information about the regulation of the markers studied. Many of the molecules were expressed at similar levels on both TILs and allostimulated T cells, reflecting similarities in culture and activation between the two T-cell preparations. However, marked differences were observed for other markers. Firstly, three molecules were expressed at twofold higher levels on TILs than allostimulated T cells: (a) the cutaneous lymphocyte-associated antigen, CLA; (b) CD69, an acute activation marker; and (c) CD3 1, an adhesion-inducing molecule . Secondly, 12 molecules were expressed at higher levels on allostimulated T cells than on TIL: (a) the integrins a407, WIELP7, CD49b, CD49d, and CD1 lb; (b) the adhesion molecules CD99 (E2), CD43, CD44 and CD54; and (c) activation antigens CD25, CD38 (OKTlO) and CD71.
Adhesion molecules show heterogeneity of expression within and between TIL preparations
Median channel fluorescence provides a statistical summary of complex data that conceal heterogeneity both within a given cell preparation and between preparations. Both kinds of heterogeneity are illustrated in Figure 4 . One of the least heterogeneous molecules is the integrin LFA-1; although median fluorescence is consistent between the three profiles, there is marked heterogeneity within one of the TIL preparations, demonstrating that even LFA-1 is differentially regulated on different cells. Such Figure 4 Histograms of selected molecules comparing expression on TIL with PBT. Each panel shows staining for PBT (dashed line) and two TIL preparations: the two TIL preparations shown for a marker are ones whose median channel fluorescence is either side of the median TIL for all seven patients heterogeneity was seen with most of the markers. Heterogeneity between TIL is illustrated by VLA-4. Even these two TILs that are close to the 'median TIL' differ substantially from each other. Because of the averaging process, VLA-4 does not appear to be remarkable in Figure 2 . As data are collected on a four-decade log scale, a twofold difference corresponds to about 20 channels. Thus, the TIL shown differ more than 10-fold in median expression of VLA-4.
Among the other adhesion molecules, we illustrate two that are increased on TILs (CLA and HML-1) and two that are reduced several-fold compared with PBTs. Among the traditional 'activation markers' (CD69, HLA class II, CD30, CD38), three are increased but one is decreased from its low basal expression on resting T cells (CD38).
TILs display strong activation-independent binding to endothelium
We investigated the capacity of TILs to bind to endothelium in standard in vitro assay of leucocyte binding to cultured human umbilical vein endothelial cells (HUVECs) (Figures 5 and 6 ) and a transformed skin-derived microvascular endothelial cell line (HMEC-1) (Figure 6 ). TILs bound avidly. More than 50% of TILs bound to resting endothelium, whereas only 10-15% of resting PBTs bound. Activation of TILs by phorbol ester did not cause a further increase in binding, suggesting that integrins on TILs are already fully activated. This contrasts with the marked increase in PBT adhesion to both resting and activated endothelium after phorbol ester stimulation ( Figure 5 ). 3. E-selectin on endothelium to its carbohydrate ligand on TILs (CLA and/or another carbohydrate receptor).
The blocking antibodies were used either alone or in combinations of two and three antibodies to allow the contribution of each pathway to be assessed as described previously (Shimizu et al, 1991a) .
TILs binding to resting endothelium involved ,2 integrins and to a lesser extent PI integrins ( Figure 6A to that for HMEC-1 ( Figure 6A ). E-selectin is not expressed on resting endothelium and was therefore not involved. Binding to activated endothelium involves integrins and selectinmediated pathways. Activation of endothelium by exposure to either IL-1 (HUVEC) or TNF-ox (HMEC-1) increased the percentage of TILs that bound ( Figure 6B vs 6A ). As seen with resting endothelium, binding to activated endothelium involved both PI and 32 integrins, with the P2 integrin pathway dominating (01 integrin compared with control, 2P = 0.07; P2 integrin, 2P < 0.001; 1+ 32, 2P < 0.0006; [Il+P2 compared with P2 alone, 2P < 0.002). Eselectin MAb, by itself, had no effect on binding; however, addition of E-selectin MAb to the mix of 1/,B2 MAb caused a small but definite reduction in TIL binding to HUVECs compared with PI1 /2 mix alone but had no effect when HMEC-1 endothelial cells were used, which is consistent with the very low levels of E-selectin expressed on HMEC-1 in our culture system (data not shown). Overall, the pattern of adhesion inhibition for unactivated TILs is similar to the pattern with PMA-activated PBTs.
British Journal of Cancer (1997) 75(10) (Rosenberg et al, 1986) . The therapeutic efficacy of TILs will depend on two interrelated factors: their ability to mount an effective anti-tumour response on encountering tumour cells (Itoh et al, 1986; Spiess et al, 1987; Aebersold et al, 1990; Yannelli, 1991) and, equally important, their ability to reach tumour sites in sufficient numbers to have a clinically significant effect. Relatively little is known about the factors that regulate TIL recruitment to tumour sites, despite the fact that such factors will be crucial for the clinical efficacy of TILs (Whiteside and Herberman, 1992) .
Before cultured TILs can migrate from the circulation into tissue they must first recognize and bind to tumour endothelium, a process determined by the adhesion molecules expressed on TILs and the presence of appropriate ligands on tumour endothelium (Butcher, 1991; Shimizu et al, 1992; Whiteside and Herberman, 1992) . In the present study we determined the detailed phenotype of cultured TILs, with particular reference to the adhesion molecules they express, and assessed their ability to bind to endothelium in vitro. We found gross differences between TILs and normal circulating T cells that are likely to have a profound effect on the migratory behaviour of infused TIL in vivo.
Cultured TILs showed enhanced binding to both resting and activated endothelium that was mediated largely by LFA-1 and VLA-4, the most important T-cell integrins in endothelial-binding (Shimizu et al, 1991a . Furthermore, treatment of TILs with phorbol ester did not increase binding, suggesting that integrins on TILs are fully activated. This is in marked contrast to the low levels of integrin-mediated binding seen with resting peripheral blood T cells in the absence of activation ( Figure 5 ; Shimizu et al, 1991a) . This activation-independent adhesion is not merely a reflection of increased surface expression of integrins on TIL (Figure 2 ), but rather of an altered functional state of those integrins.
What are the potential implications of these findings for TILs homing in vivo? Increased integrin activation on cultured TILs will disrupt the normal regulation of endothelial binding. On the one hand, this might increase the numbers of TILs binding to tumour endothelium and thereby increase the numbers entering tumour tissue. However, the specificity of endothelial binding will be lost, with the consequence that TILs can bind to multiple vascular beds as well as to tumour endothelium with a consequent reduction in the specificity of TIL migration. In particular, this is likely to occur in the sinusoids of the liver and spleen and in the small vessels of the lung where cells come into intimate contact with endothelium that constitutively expresses ICAM-1 and, in the case of the lung and liver, low levels of VCAM-l (Rice et al, 1991; Adams et al, 1994; Dunkley et al, 1995) . The larger, more irregular shape of TILs (Figure 1 ; Whiteside and Herberman, 1992) will reduce their deformability and lead to increased contact between circulating TIL and the wall of small vessels, thereby allowing time for the activated integrins to engage these endothelial ligands (Adams and Nash, 1996) . This is particularly likely to happen in low-flow systems, such as the hepatic and splenic sinusoids . In addition, the large size of TILs will result in physical trapping in the small-calibre vessels of organs such as the lung (Adams and Nash, 1996) . These concerns are supported by clinical studies in which indium-labelled TILs were infused into patients and their in vivo distribution subsequently assessed by scanning with a gammacamera. The vast majority of the infused cells were detected in the liver, spleen and lung within minutes of infusion, and only a small proportion reached tumour deposits (Poppema et al, 1983; Griffith et al, 1989) . This inefficient trafficking of cultured TILs is in contrast to the efficient removal of relevant T cells from the circulation that occurs in normal homing (Fisher and Ottaway, 1990; Picker and Butcher, 1992 (Picker et al, 1990a) . CLA, a heavily glycosylated carbohydrate epitope on cell surface glycoproteins, is expressed at low levels on less than 20% of PBT (Berg et al, 1991; Picker et al, 1993a) . In vivo, CLA is expressed on cutaneous lymphomas (Picker et al, 1990a ) and on 85% of T cells at sites of skin inflammation (Picker et al, 1990a ).
In contrast, it is detected on less than 5% of T cells in inflamed non-cutaneous sites . CLA has therefore been proposed as a skin homing receptor (Picker and Butcher, 1992 ). As we found high levels of expression of CLA on most of the TIL preparations and as melanoma endothelium expresses the CLA receptor E-selectin (Rohde et al, 1992) , the CLA-E-selectin interaction may facilitate TIL migration into melanoma. The fact that we did not see a major contribution from E-selectin in the adhesion assays may be because E-selectin/CLA mediates the initial tethering adhesion that leads to rolling of the T cell on the vessel wall. Static adhesion assays do not reflect the significance of this step because integrin binding dominates in such systems (Spertini et al, 1991) . Thus, the small effect we saw with anti-E-selectin is unlikely to be a true reflection of its contribution in vivo. The presence of CLA on TILs would promote binding to E-selectin on tumour endothelium in vivo, resulting in tethering -the first step in the adhesion cascade. The usual requirement for a second step to trigger integrin activation would be bypassed because of the preactivated status of TIL integrins, allowing them to engage their ligands, ICAM-1 and VCAM-1, on tumour endothelium (Rohde et al, 1992) . LFA-1 might be expected to dominate as ICAM-1 is expressed on tumour endothelium at far greater levels than VCAM-1 (Rohde et al, 1992) . From our studies it would appear that CLA expression is a characteristic of these TIL rather than an effect of their culture conditions. The findings that support this conclusion are:
1. the expression of CLA does not increase on peripheral blood T cells activated with mitogens in vitro (Picker et al, 1993a ); 2. CLA was one of only three antigens that showed increased expression on TIL compared with allostimulated T cells; 3. TILs may have a homing 'phenotype' characteristic of skin, as TILs also expressed lower levels of the gut homing receptors czIELf7 and a437 (Picker et al, 1 990b; Schweighoffer et al, 1993) compared with alloantigen-stimulated T cells;
4. CLA is not expressed by TILs derived from either primary hepatic tumours or primary or secondary colonic carcinoma (Yoong and Adams, unpublished observations; .
Thus, the CLA-high/LFA-1-high/a4,B7-low/aIEL07-low phenotype of TILs would be predicted to favour homing to skin tissues (Picker and Butcher, 1992; Picker et al, 1993a; Schweighoffer et al, 1993) . If the highly activated state of LFA-l and VLA-4 on TILs could be reduced to prevent non-specific adhesion to other vascular beds, this tissue-specific homing phenotype should result in efficient recruitment of infused TILs to tumour. The endothelial cell line we used in the adhesion studies, HMEC-1, is derived from microvascular endothelium in the skin. However, this cell line may differ substantially from the endothelium within melanoma tumour tissue in vivo and, in the long run, it will be important to understand details of interactions of TILs with various specialized kinds of endothelium, including endothelium in tumour vessels.
Other molecules with potential roles in endothelial binding that were detected on TILs included CD3 1, CD43 and CD44. CD3 1, a member of the immunoglobulin superfamily, has a unique distribution on peripheral blood T cells, being expressed on all naive CD8 T cells, 50% of CD8 memory cells and 50% of CD4 naive cells. CD31 expression was heterogeneous both within and between TIL preparations. The CD4 TIL preparation studied was largely negative, as might be expected from the distribution of CD31 in peripheral blood T cells. Although there was variation in the expression of CD31 between different CD8 TIL preparations, all of them contained a substantial subset of cells that were CD31 positive (Table 1) , and it is possible that CD31 expression might have facilitated the original entry of this TILs into tumour. This is supported by the proposal that CD31 on T cells can act as an amplifier of T-cell integrin function when it engages an, as yet unknown, endothelial receptor Tanaka et al, 1992) and by recent studies proposing a role for CD31 in the entry of TILs into murine tumours (Schmitt-Verhulst, 1994 ) (B Imhof, personal communication). However, CD31 expression cannot be an absolute requirement for TIL recruitment as the CD31-dull CD4+ TILs that we studied (TIL6) migrated to tumour deposits in vivo.
Both CD43 and CD44 were reduced on TILs compared with PBTs. CD44 is an abundant multifunctional cell surface molecule that was initially inferred to be a tissue-specific homing receptor (Jalkanen et al, 1987) . However, because of its broad tissue distribution it may have a more general role in facilitating binding to endothelium via its ligand hyaluronate (Aruffo et al, 1990) .
Decreased CD44 on TILs may therefore reduce efficiency of endothelial binding. In contrast, reduced expression of CD43, the predominant cell surface mucin on lymphocytes (/) on TILs might be expected to increase endothelial adhesion (McLean, 1994) . The inference that mucins maintain a repulsive barrier around the cell is based on findings with CD43 (Ardman et al, 1992; Manjunath et al, 1993) . For example, targeted disruption of the CD43 gene in the T-cell line CEM enhances homotypic adhesion and binding to fibronectin (Manjunath et al, 1993) .
In addition to the 'adhesion molecules' discussed above, TILs also differ from PBTs in their expression of 'activation markers'. Most of these activation markers are expressed more on TILs than on PBTs (e.g. CD30, CD39, CD69, HLA class II). An exception is CD38, usually considered to be an activation marker, which is expressed at lower levels on TILs than on PBTs. These molecules may be important for TIL function. For instance, CD69 is a C-type lectin (Lopez-Cabera et al, 1993) likely to contribute to adhesion and CD38 has been implicated in binding to endothelium (Xu et al, 1994) . Furthermore, both CD69 and CD38 are involved in signal transduction and cell activation (Nakamura et al, 1989; Moretta et al, 1991; Tugores et al, 1992; Xu et al, 1994) and CD30, a member of the TNF receptor family, could modulate TIL effector function by interacting with the CD30 ligand in the tumour (Faustman et al, 1982) .
Although all these molecules are expressed with cellular activation, they show different regulation with respect to which subsets of cells express them, which signals induce them and the kinetics of their expression (Crabtree, 1989) . This is illustrated by the contrast between TILs and alloactivated T cells ( Figure 3) ; CD69 and CD30 are expressed at higher levels on TILs, whereas CD25 and CD38 are expressed at higher levels on allostimulated T cells. Thus, the detailed phenotype of these activated T cells is regulated in a complex manner that depends in part on the original character of the activated cell as well as on the exact details/timing of culture.
The fact that the phenotype of TILs is influenced by the details of their culture implies that it is susceptible to modification. As the physiological homing of T cells is highly selective and exquisitely regulated, the generation of TILs with a more physiological phenotype might result in restoration of their specific homing potential. The aim of such manipulation would be to maintain expression of molecules that are unique to TIL, such as the skin homing receptor CLA, while reducing the non-specific activation of, for instance, integrins, thereby allowing the original character of the TILs to emerge. Theoretically, such a strategy could produce TILs that show reduced binding to endothelium in normal tissues but maintain their ability to selectively bind tumour endothelium, thereby increasing delivery to tumour sites. These observations have wider implications with the increasing use of cultured leucocytes and adoptive immunotherapy in other clinical situations.
